Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial.

Bedlack RS, Wicks P, Vaughan T, Opie A, Blum R, Dios A, Sadri-Vakili G.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):285-293. doi: 10.1080/21678421.2018.1556698. Epub 2019 Jan 21.

PMID:
30663902
2.

Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis.

Wolpaw JR, Bedlack RS, Reda DJ, Ringer RJ, Banks PG, Vaughan TM, Heckman SM, McCane LM, Carmack CS, Winden S, McFarland DJ, Sellers EW, Shi H, Paine T, Higgins DS, Lo AC, Patwa HS, Hill KJ, Huang GD, Ruff RL.

Neurology. 2018 Jul 17;91(3):e258-e267. doi: 10.1212/WNL.0000000000005812. Epub 2018 Jun 27.

3.

Refractory myasthenia gravis exacerbation triggered By pembrolizumab.

Earl DE, Loochtan AI, Bedlack RS.

Muscle Nerve. 2018 Apr;57(4):E120-E121. doi: 10.1002/mus.26021. Epub 2017 Dec 7. No abstract available.

PMID:
29193151
4.

Treatment of Thymoma-Associated Myasthenia Gravis With Stereotactic Body Radiotherapy: A Case Report.

Lee CM, Lee JD, Hobson-Webb LD, Bedlack RS, Salama JK.

Ann Intern Med. 2016 Aug 16;165(4):300-1. doi: 10.7326/L15-0469. Epub 2016 Mar 15. No abstract available.

PMID:
26974367
5.

Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.

Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS.

Neurology. 2016 Mar 1;86(9):813-20. doi: 10.1212/WNL.0000000000002305. Epub 2016 Jan 22.

6.

How common are ALS plateaus and reversals?

Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, Macklin EA, Schoenfeld D, Cudkowicz M, Sherman A.

Neurology. 2016 Mar 1;86(9):808-12. doi: 10.1212/WNL.0000000000002251. Epub 2015 Dec 9.

7.

Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Bedlack RS, Joyce N, Carter GT, Paganoni S, Karam C.

Neurol Clin. 2015 Nov;33(4):909-36. doi: 10.1016/j.ncl.2015.07.008. Epub 2015 Sep 8. Review.

8.

Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.

Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu YF, Wang Q, Krueger BJ, Ren Z, Keebler J, Han Y, Levy SE, Boone BE, Wimbish JR, Waite LL, Jones AL, Carulli JP, Day-Williams AG, Staropoli JF, Xin WW, Chesi A, Raphael AR, McKenna-Yasek D, Cady J, Vianney de Jong JM, Kenna KP, Smith BN, Topp S, Miller J, Gkazi A; FALS Sequencing Consortium, Al-Chalabi A, van den Berg LH, Veldink J, Silani V, Ticozzi N, Shaw CE, Baloh RH, Appel S, Simpson E, Lagier-Tourenne C, Pulst SM, Gibson S, Trojanowski JQ, Elman L, McCluskey L, Grossman M, Shneider NA, Chung WK, Ravits JM, Glass JD, Sims KB, Van Deerlin VM, Maniatis T, Hayes SD, Ordureau A, Swarup S, Landers J, Baas F, Allen AS, Bedlack RS, Harper JW, Gitler AD, Rouleau GA, Brown R, Harms MB, Cooper GM, Harris T, Myers RM, Goldstein DB.

Science. 2015 Mar 27;347(6229):1436-41. doi: 10.1126/science.aaa3650. Epub 2015 Feb 19.

9.

SAPs: a different perspective.

Rabourn J, Bedlack RS.

Am J Bioeth. 2014;14(11):19-20. doi: 10.1080/15265161.2014.957621. No abstract available.

PMID:
25325804
10.

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24.

11.

Creatine for amyotrophic lateral sclerosis/motor neuron disease.

Pastula DM, Moore DH, Bedlack RS.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD005225. doi: 10.1002/14651858.CD005225.pub3. Review.

PMID:
23235621
12.

Diaphragm pacing in amyotrophic lateral sclerosis: a literature review.

Scherer K, Bedlack RS.

Muscle Nerve. 2012 Jul;46(1):1-8. doi: 10.1002/mus.23419. Review.

PMID:
22692995
13.

Pesticide exposure and amyotrophic lateral sclerosis.

Kamel F, Umbach DM, Bedlack RS, Richards M, Watson M, Alavanja MC, Blair A, Hoppin JA, Schmidt S, Sandler DP.

Neurotoxicology. 2012 Jun;33(3):457-62. doi: 10.1016/j.neuro.2012.04.001. Epub 2012 Apr 12. Review.

14.

Compassionate use of stem cells for ALS: popovers and hot air.

Bedlack RS.

Amyotroph Lateral Scler. 2011 Sep;12(5):313-4. doi: 10.3109/17482968.2011.583743. Epub 2011 May 9. No abstract available.

PMID:
21554029
15.

Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.

Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupler E, Lou JS, Ensrud E, Tan E, Goldstein JM, Katz J, Dimachkie MM, Barohn RJ, Mozaffar T.

J Neuropathol Exp Neurol. 2011 Jan;70(1):96-7; author reply 98-100. doi: 10.1097/NEN.0b013e318204782b. No abstract available.

PMID:
21173608
16.

Amyotrophic lateral sclerosis: current practice and future treatments.

Bedlack RS.

Curr Opin Neurol. 2010 Oct;23(5):524-9. doi: 10.1097/WCO.0b013e32833c7ac2. Review.

PMID:
20613515
17.

Creatine for amyotrophic lateral sclerosis/motor neuron disease.

Pastula DM, Moore DH, Bedlack RS.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005225. doi: 10.1002/14651858.CD005225.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD005225.

PMID:
20556761
18.

Modifiable barriers to enrollment in American ALS research studies.

Bedlack RS, Wicks P, Heywood J, Kasarskis E.

Amyotroph Lateral Scler. 2010 Dec;11(6):502-7. doi: 10.3109/17482968.2010.484494. Epub 2010 May 7.

PMID:
20446890
19.

Factors associated with survival in the National Registry of Veterans with ALS.

Pastula DM, Coffman CJ, Allen KD, Oddone EZ, Kasarskis EJ, Lindquist JH, Morgenlander JC, Norman BB, Rozear MP, Sams LA, Sabet A, Bedlack RS.

Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):332-8. doi: 10.3109/17482960802320545.

PMID:
19922120
20.

Lyme disease serology in amyotrophic lateral sclerosis.

Qureshi M, Bedlack RS, Cudkowicz ME.

Muscle Nerve. 2009 Oct;40(4):626-8. doi: 10.1002/mus.21438.

PMID:
19697382
21.

Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance.

Bedlack RS, Cudkowicz ME.

Front Neurol Neurosci. 2009;25:144-151. doi: 10.1159/000209493. Epub 2009 Mar 19. No abstract available.

PMID:
19478515
22.

Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis.

Khishchenko N, Allen KD, Coffman CJ, Kasarskis EJ, Lindquist JH, Morgenlander JC, Norman BB, Oddone EZ, Rozear MP, Sabet A, Sams L, Bedlack RS.

Amyotroph Lateral Scler. 2010;11(1-2):125-32. doi: 10.3109/17482960802572681.

PMID:
19153849
23.

IPLEX and the telephone game: the difficulty in separating myth from reality on the internet.

Bedlack RS, Silani V, Cudkowicz ME.

Amyotroph Lateral Scler. 2009 Jun;10(3):182-4. doi: 10.1080/17482960802673059. No abstract available.

PMID:
19110985
24.

Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease.

Bedlack RS, Pastula DM, Hawes J, Heydt D.

Amyotroph Lateral Scler. 2009 Aug;10(4):210-5. doi: 10.1080/17482960802430773.

PMID:
18821142
25.

Phase 2 study of sodium phenylbutyrate in ALS.

Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ; Northeast ALS and National VA ALS Research Consortiums.

Amyotroph Lateral Scler. 2009 Apr;10(2):99-106. doi: 10.1080/17482960802320487.

PMID:
18688762
26.

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelinas DF, Lou JS.

Amyotroph Lateral Scler. 2008 Oct;9(5):266-72. doi: 10.1080/17482960802028890.

27.

Scrutinizing enrollment in ALS clinical trials: room for improvement?

Bedlack RS, Pastula DM, Welsh E, Pulley D, Cudkowicz ME.

Amyotroph Lateral Scler. 2008 Oct;9(5):257-65. doi: 10.1080/17482960802195913.

PMID:
18608092
28.

The National Registry of Veterans with amyotrophic lateral sclerosis.

Allen KD, Kasarskis EJ, Bedlack RS, Rozear MP, Morgenlander JC, Sabet A, Sams L, Lindquist JH, Harrelson ML, Coffman CJ, Oddone EZ.

Neuroepidemiology. 2008;30(3):180-90. doi: 10.1159/000126910. Epub 2008 Apr 18.

PMID:
18421218
29.

Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed.

Bedlack RS, Maragakis N, Heiman-Patterson T.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):E17; author reply E18. doi: 10.1073/pnas.0801762105. Epub 2008 Apr 16. No abstract available.

30.

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R; Western ALS Study Group.

Lancet Neurol. 2007 Dec;6(12):1045-53. Epub 2007 Nov 5.

PMID:
17980667
31.

Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis.

Bedlack RS, Traynor BJ, Cudkowicz ME.

Expert Opin Emerg Drugs. 2007 May;12(2):229-52. Review.

PMID:
17604499
32.

Dysarthria and dysphagia from light chain amyloidosis.

Tabbarah K, Madden J, Bedlack RS.

Neurology. 2005 Nov 22;65(10):1671. No abstract available.

PMID:
16301506
33.

Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity.

Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB.

Neurology. 2005 Jun 14;64(11):1968-70.

PMID:
15955957
34.

Does this patient have myasthenia gravis?

Scherer K, Bedlack RS, Simel DL.

JAMA. 2005 Apr 20;293(15):1906-14. Review.

PMID:
15840866
35.

MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy.

Bedlack RS, Vu T, Hammans S, Sparr SA, Myers B, Morgenlander J, Hirano M.

Muscle Nerve. 2004 Mar;29(3):364-8.

PMID:
14981734
36.

APOE genotype is a risk factor for neuropathy severity in diabetic patients.

Bedlack RS, Edelman D, Gibbs JW 3rd, Kelling D, Strittmatter W, Saunders AM, Morgenlander J.

Neurology. 2003 Mar 25;60(6):1022-4.

PMID:
12654974
37.

On the concept of myasthenic crisis.

Bedlack RS, Sanders DB.

J Clin Neuromuscul Dis. 2002 Sep;4(1):40-2.

PMID:
19078687
38.

Steroid treatment for myasthenia gravis: steroids have an important role.

Bedlack RS, Sanders DB.

Muscle Nerve. 2002 Jan;25(1):117-21. Review. No abstract available.

PMID:
11754196
39.

Apolipoprotein E and neuromuscular disease: a critical review of the literature.

Bedlack RS, Strittmatter WJ, Morgenlander JC.

Arch Neurol. 2000 Nov;57(11):1561-5. Review.

PMID:
11074787
40.

Hidden afterdischarges in slow channel congenital myasthenic syndrome.

Bedlack RS, Bertorini TE, Sanders DB.

J Clin Neuromuscul Dis. 2000 Jun;1(4):186-90.

PMID:
19078585
41.

How to handle myasthenic crisis. Essential steps in patient care.

Bedlack RS, Sanders DB.

Postgrad Med. 2000 Apr;107(4):211-4, 220-2. Review.

PMID:
10778421
42.

Transient lumbosacral polyradiculopathy after prostatectomy: association with spinal stenosis.

Ahearn GS, Bedlack RS, Price DT, Robertson CN, Morgenlander JC.

South Med J. 1999 Aug;92(8):809-11.

PMID:
10456722
43.

Succinylcholine induced hyperkalemia and cardiac arrest death related to an EEG study.

Verma A, Bedlack RS, Radtke RA, VanLandingham KE, Erwin CW.

J Clin Neurophysiol. 1999 Jan;16(1):46-50.

PMID:
10082091
44.

Distinct electric potentials in soma and neurite membranes.

Bedlack RS Jr, Wei MD, Fox SH, Gross E, Loew LM.

Neuron. 1994 Nov;13(5):1187-93.

PMID:
7946355
45.

Dual-wavelength ratiometric fluorescence measurement of the membrane dipole potential.

Gross E, Bedlack RS Jr, Loew LM.

Biophys J. 1994 Jul;67(1):208-16.

46.

Supplemental Content

Loading ...
Support Center